Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies

Giuseppina Bonanno, Annabella Procoli, Andrea Mariotti, Maria Corallo, Alessandro Perillo, Silvio Danese, Raimondo De Cristofaro, Giovanni Scambia, Sergio Rutella

Research output: Contribution to journalArticle

Abstract

Background: Pegylated granulocyte colony-stimulating factor (G-CSF; pegfilgrastim) is a longer-acting form of G-CSF, whose effects on dendritic cell (DC) and regulatory T cell (Treg) mobilization, and on the in vivo and ex vivo release of immune modulating cytokines remain unexplored.Methods: Twelve patients with gynecological cancers received carboplatin/paclitaxel chemotherapy and single-dose pegfilgrastim as prophylaxis of febrile neutropenia. Peripheral blood was collected prior to pegfilgrastim administration (day 0) and on days +7, +11 and +21, to quantify immunoregulatory cytokines and to assess type 1 DC (DC1), type 2 DC (DC2) and Treg cell mobilization. In vitro-differentiated, monocyte-derived DC were used to investigate endocytic activity, expression of DC maturation antigens and ability to activate allogeneic T-cell proliferation.Results: Pegfilgrastim increased the frequency of circulating DC1 and DC2 precursors. In contrast, CD4+FoxP3+ bona fide Treg cells were unchanged compared with baseline. Serum levels of hepatocyte growth factor and interleukin (IL)-12p40, but not transforming growth factor-β1 or immune suppressive kynurenines, significantly increased after pegfilgrastim administration. Interestingly, pegfilgrastim fostered in vitro monocytic secretion of IL-12p40 and IL-12p70 when compared with unconjugated G-CSF. Finally, DC populations differentiated in vitro after clinical provision of pegfilgrastim were phenotypically mature, possessed low endocytic activity, and incited a robust T-cell proliferative response.Conclusions: Pegfilgrastim induced significant changes in immune cell number and function. The enhancement of monocytic IL-12 secretion portends favorable implications for pegfilgrastim administration to patients with cancer, a clinical context where the induction of immune deviation would be highly undesirable.

Original languageEnglish
Article number114
JournalJournal of Translational Medicine
Volume8
DOIs
Publication statusPublished - Nov 9 2010

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Bonanno, G., Procoli, A., Mariotti, A., Corallo, M., Perillo, A., Danese, S., De Cristofaro, R., Scambia, G., & Rutella, S. (2010). Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies. Journal of Translational Medicine, 8, [114]. https://doi.org/10.1186/1479-5876-8-114